Nivolumab with ipilimumab in the treatment of malignant pleural mesothelioma – GOV.UK

  • Whatsapp

We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You can change your cookie settings at any time.
Find information and services
Search for a department and find out what the government is doing
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Government data, Freedom of Information releases and corporate reports
EAMS scientific opinion issued to Bristol-Myers Squibb Pharmaceuticals Limited for nivolumab to be used in combination with ipilimumab in the treatment of malignant pleural mesothelioma (a type of cancer that affects the lining of the lung) in adults.
PDF, 729KB, 4 pages
This file may not be suitable for users of assistive technology.
HTML
PDF, 689KB, 24 pages
This file may not be suitable for users of assistive technology.
HTML
PDF, 206KB, 10 pages
This file may not be suitable for users of assistive technology.
HTML
PDF, 143KB, 4 pages
This file may not be suitable for users of assistive technology.
HTML
PDF, 125KB, 5 pages
This file may not be suitable for users of assistive technology.
HTML
For the full EAMS indication please see section 4.1 of the Treatment protocol: Information for healthcare professionals.
The scientific opinion includes:
a public assessment report (PAR)
For new patients wishing to access EAMS medicines in England, trusts must register patients on the NHS England web-based registration system. Queries to NHS England regarding the scheme can be submitted to [email protected]
For information about access in Northern Ireland, contact Chief Pharmaceutical Officer and Joe Magee, Secondary Care Directorate at [email protected].
For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care at [email protected]
For information about access in Wales, contact the Welsh Government Health and Social Services Group by emailing Andrew Evans, Chief Pharmaceutical Officer or Lynne Schofield, Head of Pharmacy and Prescribing policy at [email protected]
Check what you need to do
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.

source

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *